Oral ibuprofen is more effective than intravenous ibuprofen for closure of a patent ductus arteriosus: can pharmacokinetic modelling help us to understand why?

Dataset as used for paper in Neonatology 2022. <br> Oral ibuprofen is more effective than intravenous ibuprofen for closure of a patent ductus arteriosus: can pharmacokinetic modelling help us to understand why? <br> Authors: Cornelis Smit (Co-author), Aline G.J. Engbers (Co-author), Samira Samiee-Zafarghandy (Co-author), Tamara van Donge (Co-author), Sinno H.P Simons (Co-author), Robert B. Flint (Co-author), Marc Pfister (Co-author), Catherijne A.J. Knibbe (Corresponding author), John N. van den Anker (Co-author)<br> <br> Non-commercial use only under CC BY-NC licence. <br> <br> DATA DICTIONARY <br> # ID STUDY A STARTS WITH 2000, STUDY B AT 1 # TIME IN HOUR # AMT IN MG (50% FOR EACH ENANTIOMERE) # RATE IN MG/H FOR IV, ORAL = 0 # DV IN MG/L # MDV # CMT 1 abs s-ibu 3 abs r-ibu 2 conc s-ibu 4 conc r-ib # EVID # TAD TIME AFTER DOSE IN H # DV_TOT SUM OF R-IBU AND S-IBU DV # ENANT S-IBU = 1 R-IBU = 2 # ROA 1 = IV 2 = PO # BLOQ 1: sample was detectable, a concentration could be measured. Measured concentration is presented in DV column. # 2: sample was detectable but concentration was below the lower limit of quantification (1 µg/ml for both S- and R-ibuprofen). Measured concentration is presented in DV column. # 3: sample was non-detectable. Concentration in DV column is set at 0 µg/ml. # 0: BLOQ = 0 if was previously NA, including all DONGE samples. <br> # BWT BODY WEIGHT IN G # CWT TIME VARYING BODY WEIGHT # IPNA INTIAIL PNA IN DAYS AT START # CPNA TIME VARYING PNA IN DAYS # SEX_F GENDER, FEMALE = 1 # SGA YES = 1 below expected 10th percentile for GA # GA gestational age in weeks # FLUCO Fluconazol used max 7 days before first or 7 days after last dose = 1 # PMA POSTMENSTRUAL AGE IN WEEKS # STD STUDY A = 1 STUDY B = 2

本数据集用于2022年发表于学术期刊《新生儿学》（Neonatology）的研究论文。
《口服布洛芬用于动脉导管未闭（patent ductus arteriosus, PDA）闭合的疗效优于静脉输注布洛芬：药代动力学建模能否助力阐明其潜在机制？》
作者：Cornelis Smit（共同作者）、Aline G.J. Engbers（共同作者）、Samira Samiee-Zafarghandy（共同作者）、Tamara van Donge（共同作者）、Sinno H.P Simons（共同作者）、Robert B. Flint（共同作者）、Marc Pfister（共同作者）、Catherijne A.J. Knibbe（通讯作者）、John N. van den Anker（共同作者）

本数据集仅可在知识共享署名-非商业性使用（CC BY-NC）许可协议框架下进行非商业性使用。

数据字典
# 研究ID：研究A的ID以2000为前缀，研究B的ID以1为前缀
# 时间：单位为小时
# 给药剂量（mg）：布洛芬对映体各占50%
# 给药速率（mg/h）：静脉给药为对应输注速率，口服给药速率记为0
# 血药浓度（mg/L）
# 缺失因变量（MDV）
# 房室编号（CMT）：1=S-布洛芬吸收室，3=R-布洛芬吸收室，2=S-布洛芬浓度室，4=R-布洛芬浓度室
# 事件标识（EVID）
# TAD：给药后时长，单位为小时
# DV_TOT：R-布洛芬与S-布洛芬血药浓度的总和
# 对映体类型（ENANT）：1=S-布洛芬，2=R-布洛芬
# 给药途径（ROA）：1=静脉给药（intravenous, IV），2=口服给药（per os, PO）
# BLOQ：1=样本可检出，可准确定量，浓度值列于DV列；2=样本可检出，但浓度低于定量下限（lower limit of quantification, LLOQ）（S-、R-布洛芬均为1 µg/ml），浓度值仍列于DV列；3=样本未检出，DV列浓度值设为0 µg/ml；0=若原始值为NA则BLOQ记为0，涵盖所有van Donge样本
# 体质量（BWT）：单位为克
# 时变体质量（CWT）
# 初始生后年龄（IPNA）：首次给药时的生后年龄，单位为天，生后年龄（postnatal age, PNA）
# 时变生后年龄（CPNA）：时变的生后年龄，单位为天
# 性别标记（SEX_F）：女性记为1
# 小于胎龄儿（SGA）：出生胎龄对应第10百分位以下则记为1
# 胎龄（GA）：单位为周
# 氟康唑使用标记（FLUCO）：首次给药前7天内或末次给药后7天内使用氟康唑则记为1
# 矫正胎龄（PMA）：单位为周，postmenstrual age, PMA
# 研究分组（STD）：研究A记为1，研究B记为2